[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638236":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":19,"responsibleParty":26,"collaborators":28,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":19,"enrollmentInfo":41,"targetDuration":19,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":56,"whyStopped":19,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":19},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"study population","EXPERIMENTAL","Procedure: Patients included in the ANRS0758s MOSAIC cohort will be recalled \\>3 years after their infection to come to hospital to have a review of medical history since mpox infection, a clinical examination in case of symptoms suggestive of a mpox infection and samples taken for the study.",[13],"Procedure: blood sampling",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"PROCEDURE","blood sampling",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Aida TAIEB","CONTACT","+33 (0)1 82 53 35 66","aida.taieb@inserm.fr",{"type":27,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[29],{"name":30,"class":31},"Assistance Publique - Hôpitaux de Paris","OTHER","100638236","assessment-of-immune-memory---humoral-and-cellular---in-mpox-infected-patients--an-ancillary-study-of-the-anrs0258s-mosaic-cohort-100638236",false,"NCT07592429","Assessment of Immune Memory - Humoral and Cellular - in mPOX-infected Patients : an Ancillary Study of the ANRS0258s MOSAIC Cohort","POXAIM","Inclusion Criteria:\n\n* Written informed consent, signed by the participant and the investigator prior to any study-related procedure\n* Person previously enrolled in the ANR0258s-MOSAIC cohort (see Appendix 19.2 for MOSAIC inclusion criteria) between July 2022 and July 2023\n* Person with a blood sample taken within 8 months following mpox infection\n* ≥ 18 years old\n\nExclusion Criteria:\n\n* Individuals who, in the investigator's opinion, are unlikely to comply with study procedures or whose medical condition is incompatible with study participation\n* For France only: person not affiliated to or not benefiting from a social security scheme in accordance with article L1121-11 of the French Public Health Code (Aide Médicale d'Etat \\[AME\\] does not constitute a social security scheme)\n* Pregnant or breastfeeding women\n* Individuals under guardianship or curatorship, or deprived of liberty by judicial or administrative decision","ALL","18 Years",{"count":42,"type":43},60,"ESTIMATED","INTERVENTIONAL",[46],"NA","Primary objective The overall objective is to assess the long-term amplitude and durability of the immune responses after mpox virus (MPXV) infection.\n\nPrimary endpoint The main outcomes are: the presence of neutralizing antibodies in the serum and the presence of detectable mpox virus-specific memory B cells. Neutralizing antibodies titers will be measured with a semi-automated cell-based assay using live mpox virus. Memory B cells will be measured by flow cytometry and other techniques.\n\nSecondary objectives\n\n1. Assess the amplitude and the stability of the MPXV antigen-specific B-cell memory response after infection, against the immunodominant antigens A27, A33, B5, L1, D8, and H3.\n2. Assess the breadth of the B-cell repertoire and its neutralizing capacity in a subset of patients\n3. Assess the humoral immunity using different serological techniques, for the detection and quantification of anti-MPXV antibodies, and assess the seroneutralization capacities of each antibody.\n\nSecondary endpoints\n\n1. The presence of MPXV antigen-specific B-cell memory. Memory B cells will be measured by flow cytometry and other techniques.\n2. The breadth and neutralizing capacity of the B-cell repertoire in a subset of patients.\n3. The humoral immunity using serological techniques.",[49],"Mpox (Monkeypox)",[51,52,53,54,55],"mpox virus","Immune protection","Immune response","Immunity duration","Infection","NOT_YET_RECRUITING","2026-05-14",{"date":59,"type":60},"2026-05-18","ACTUAL",{"date":62,"type":43},"2026-07-01",{"date":64,"type":43},"2028-07-01",{"name":5,"class":6}]